METHODS OF NORMALIZING ASTHMA SYMPTOMS USING BENRALIZUMAB Russian patent published in 2025 - IPC A61K39/395 A61P11/06 C07K16/24 C07K16/28 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to pulmonology and allergology, and can be used for treating asthma. Patient is administered from approximately 2 mg to approximately 100 mg of benralizumab or its antigen-binding fragment. Effectiveness of the treatment of asthma is determined by improving the score according to the asthma assessment questionnaire in a patient with asthma, where the asthma assessment questionnaire is selected from a group consisting of an asthma control questionnaire (ACQ), asthma control questionnaire-6 (ACQ-6) and a questionnaire for assessing quality of life in patients with asthma (AQLQ). According to the questionnaire, at least one symptom selected from the group consisting of: night awakening, symptoms upon awakening, limitation of activity, shortness of breath, wheezing, use of the emergency drug preparation, frequency and severity of symptoms in the daytime, frequency and severity of symptoms at night, avoidance of activity and its limitation, asthma-related anxiety and fatigue. Benralizumab or its antigen-binding fragment can be administered from once every four weeks to once every twelve weeks from approximately 2 mg to approximately 100 mg per dose.

EFFECT: method enables treating asthma by administering benralizumab or an antigen-binding fragment thereof to a patient with asthma and determining the effectiveness of treating asthma by improving the score according to the patient’s asthma assessment questionnaire.

11 cl, 10 dwg, 4 tbl, 3 ex